Fig. 6: MCL-1 inhibitor delays progression of LUAD in vivo.
From: MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically
a Quantification of Mcl-1 mRNA in situ hybridisation in lesions from lsl-KrasG12D/+ and lsl-KrasG12D/+;p53fl/fl mice. n = number of lesions. Data are presented as box plot and were analysed by two-sided Mann-Whitney test (p = 2.57E−11). In the box plot, the centre line represents the median value, the limits represent the 25th and 75th percentile, and the whiskers represent the minimum and maximum value of the distribution. b Experimental design. Wk- week. c Representative rendering of µ-CT analysis. Scale bars represent 2 mm. d Quantification of tumour growth is expressed as percentage of the tumour volume on day 0. n = individual tumours. Three to five tumours per mouse were assessed. Data are presented as mean ± SEM and were analysed by repeated measure two-way ANOVA (time effect p < 0.0001, treatment effect p = 0.001, interaction effect p = 0.0006). Post-hoc analysis with Bonferroni correction showed a significant effect for treatment at day 14 (*p < 0.05) and day 30 (***p < 0.001).
